Impact News +++ Hermès (Hermes International) Equal Weight (DPA-AFX) +++ HERMES Aktie +3,46%

NEKTAR THERAPEUTICS Aktie

>Aktienkurs

68.08 EUR (TradegateBSX)

Ask: 69.26 EUR / 60 Stück

Bid: 66.9 EUR / 60 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: +4,8%

1 Monat: +6,0%

3 Monate: +120,6%

6 Monate: +39,6%

1 Jahr: 0%

laufendes Jahr: +87,9%

>NEKTAR THERAPEUTICS Aktie

Name:

NEKTAR THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US6402683063 / A419UB

Symbol/ Ticker:

ITH0 (Frankfurt) / NKTR (NASDAQ)

Kürzel:

FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR

Index:

Webseite:

https://www.nektar.com/

Profil:

Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and chronic inflammatory diseases in the United States an..
>Volltext..

Marktkapitalisierung:

1956.61 Mio. EUR

Unternehmenswert:

1874.43 Mio. EUR

Umsatz:

46.82 Mio. EUR

EBITDA:

-109.99 Mio. EUR

Nettogewinn:

-139.1 Mio. EUR

Gewinn je Aktie:

-8.67 EUR

Schulden:

126.24 Mio. EUR

Liquide Mittel:

2.71 Mio. EUR

Operativer Cashflow:

-176.77 Mio. EUR

Bargeldquote:

4.59

Umsatzwachstum:

-50.54%

Gewinnwachstum:

-21.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC

Letzte Datenerhebung:

15.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 28.69 Mio. St.

Frei handelbar: 96.05%

Leerverk. Aktien: 12.77%

Rückkaufquote: -7.82%

Mitarbeiter: 63

Umsatz/Mitarb.: 0.74 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 65.35%

Bewertung:

KGV: -

KGV lG: -

KUV: 29.69

KBV: 17.78

PEG-Ratio: -0.47

EV/EBITDA: -

Rentabilität:

Bruttomarge: 98.14%

Gewinnmarge: -297.07%

Operative Marge: -236.77%

Managementeffizenz:

Gesamtkaprendite: -56.17%

Eigenkaprendite: -217.94%

>Peer Group

Gesundheit, Hauterkrankungen & -behandlung/ Dermatologie, Diabetes- & Adipositas- Behandlung, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung

>Chart & Kurs - NASDAQ

>Alle News

13.04.26 - 21:48	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	BENSALEM, Pa., April 13, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU ARE AN......

13.04.26 - 09:54	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 13, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange......

13.04.26 - 08:42	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
	LOS ANGELES, April 13, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder......

10.04.26 - 17:01	NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to......

09.04.26 - 22:54	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, April 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026......

09.04.26 - 21:57	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, April 9, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO......

06.04.26 - 14:54	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange......

06.04.26 - 10:18	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
	LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder......

04.04.26 - 13:36	NKTR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to......

31.03.26 - 18:03	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, March 31, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU SUFFERED A LOSS ON YOUR......

31.03.26 - 08:06	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 31, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026......

29.03.26 - 14:39	NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nektar between February 26, 2025 and December 15, 2025 and would like to......

27.03.26 - 20:39	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	BENSALEM, Pa., March 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). IF YOU ARE AN......

26.03.26 - 04:01	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026......

25.03.26 - 22:12	Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, March 25, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO......

24.03.26 - 03:12	Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action (PR Newswire)
	SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a......

23.03.26 - 07:12	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
	LOS ANGELES, March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder......

23.03.26 - 06:12	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, March 23, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange......

21.03.26 - 06:54	NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026......

20.03.26 - 15:01	Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
	SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wir sind ebensowenig Herren unserer Träume, wie unserer Gedanken. - Voltaire

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram